Gary A. Lyons Sells 40,000 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) Director Gary A. Lyons sold 40,000 shares of the business’s stock in a transaction on Friday, October 4th. The stock was sold at an average price of $14.73, for a total value of $589,200.00. Following the completion of the transaction, the director now directly owns 51,000 shares of the company’s stock, valued at approximately $751,230. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Travere Therapeutics Price Performance

TVTX stock traded up $1.58 during trading on Friday, hitting $15.23. The stock had a trading volume of 3,178,806 shares, compared to its average volume of 2,586,679. The company’s 50-day moving average price is $11.10 and its two-hundred day moving average price is $8.68. Travere Therapeutics, Inc. has a twelve month low of $5.12 and a twelve month high of $15.46. The company has a debt-to-equity ratio of 24.96, a current ratio of 3.04 and a quick ratio of 2.99. The stock has a market capitalization of $1.16 billion, a P/E ratio of -7.25 and a beta of 0.73.

Travere Therapeutics (NASDAQ:TVTX) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.03). The company had revenue of $54.12 million for the quarter, compared to analysts’ expectations of $49.50 million. Travere Therapeutics had a negative return on equity of 269.18% and a negative net margin of 82.14%. As a group, research analysts predict that Travere Therapeutics, Inc. will post -3.95 EPS for the current fiscal year.

Hedge Funds Weigh In On Travere Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Assenagon Asset Management S.A. increased its stake in Travere Therapeutics by 912.5% during the second quarter. Assenagon Asset Management S.A. now owns 2,214,099 shares of the company’s stock worth $18,200,000 after purchasing an additional 1,995,419 shares during the period. Kynam Capital Management LP increased its stake in Travere Therapeutics by 105.6% during the 4th quarter. Kynam Capital Management LP now owns 2,000,000 shares of the company’s stock worth $17,980,000 after buying an additional 1,027,398 shares during the period. Vanguard Group Inc. boosted its position in Travere Therapeutics by 13.6% in the 1st quarter. Vanguard Group Inc. now owns 6,265,829 shares of the company’s stock valued at $48,310,000 after buying an additional 750,686 shares during the period. Millennium Management LLC grew its stake in shares of Travere Therapeutics by 33.9% in the second quarter. Millennium Management LLC now owns 2,949,335 shares of the company’s stock worth $24,244,000 after acquiring an additional 747,406 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of Travere Therapeutics in the fourth quarter worth $5,711,000.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on TVTX. Piper Sandler boosted their target price on shares of Travere Therapeutics from $11.00 to $12.00 and gave the stock a “neutral” rating in a report on Friday, August 2nd. Bank of America cut their price target on shares of Travere Therapeutics from $19.00 to $18.00 and set a “buy” rating on the stock in a research note on Friday, September 27th. Citigroup reduced their target price on Travere Therapeutics from $23.00 to $19.00 and set a “buy” rating for the company in a research note on Friday, September 27th. JPMorgan Chase & Co. boosted their price target on Travere Therapeutics from $20.00 to $23.00 and gave the company an “overweight” rating in a research note on Friday, September 13th. Finally, Barclays raised their price objective on Travere Therapeutics from $14.00 to $18.00 and gave the stock an “overweight” rating in a research note on Tuesday, October 1st. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, Travere Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.09.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.